Drug and Alcohol Dependence
Volume 88 , Pages S41-S51 , May 2007

Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection

  • Eric S. Rosenberg

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    • Center for Research in Scientific Computation, North Carolina State University, Raleigh, NC 27695-8205, USA
    • Corresponding Author InformationCorresponding author at: Massachusetts General Hospital, Department of Medicine and Pathology, Gray J-504 55 Fruit Street Boston, MA 02114, USA. Tel.: +1 617 724 7519; fax: +1 617 726 5957.
    • ,
  • Marie Davidian

      Affiliations

    • Department of Statistics, North Carolina State University, Raleigh, NC 27695-8203, USA
    • Center for Research in Scientific Computation, North Carolina State University, Raleigh, NC 27695-8205, USA
    • ,
  • H. Thomas Banks

      Affiliations

    • Center for Research in Scientific Computation, North Carolina State University, Raleigh, NC 27695-8205, USA

Received 2 April 2006 ,Revised 19 December 2006 ,Accepted 19 December 2006.

References 

  1. Adams BM, Banks HT, Davidian M, Kwon HD, Tran HT, Wynne SN, et al. HIV dynamics: modeling, data analysis, and optimal treatment protocols. J. Comp. Appl. Math. 2005;184:10–49
  2. Adams BM, Banks HT, Davidian M, Rosenberg ES. Estimation and prediction with HIV-treatment interruption data. Bull. Math. Bio. 2007;69:563–584
  3. Adams BM, Banks HT, Kwon HD, Tran HT. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 2004;1:223–242
  4. Anderson BDO, Moore JB. Optimal Control: Linear Quadratic Methods. Englewood Cliffs, NJ: Prentice-Hall; 1990;
  5. Antinori A, Cingolani A, Perno CF. Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?. AIDS. 2005;19:1691–1694
  6. Banks HT, Kunisch K. Estimation Techniques for Distributed Parameter Systems. Boston: Birkhauser; 1989;
  7. Banks HT, Kwon HD, Toivanen JA, Tran HT. An SDRE based estimator approach for HIV feedback control. J. Opt. Cont. Appl. Math. 2006;27:91–121
  8. Brandt ME, Chen G. Feedback control of a biodynamical model of HIV-1. IEEE Trans. Biomed. Eng. 2001;48:754–759
  9. Camacho EF, Bordons C. Model Predictive Control. London: Springer-Verlag; 2004;
  10. Chene G, Sterne AJ, May M, Costagliola D, Ledergerber B, Phillips A, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679–686
  11. Collins LM, Murphy SA, Bierman KL. A conceptual framework for adaptive preventive interventions. Prev. Sci. 2004;5:185–196
  12. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 1997;71:1089–1096
  13. Culshaw RV, Ruan S, Spiteri RJ. Optimal HIV treatment by maximising immune response. J. Math. Bio. 2004;48:545–562
  14. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. New York: Chapman & Hall/CRC Press; 1995;
  15. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data: an overview and update. J. Agricult. Bio. Environ. Stat. 2003;8:387–419
  16. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 2001;344:472–480
  17. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497–1503
  18. DHHS, 2005. U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at http://www.aidsinfo.nih.gov (last accessed 4/3/06).
  19. Di Mascio M, Riberio RM, Markowitz M, Ho DD, Perelson AS. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math. Biosci. 2004;188:47–62
  20. Dixit NM, Perelson AS. Complex patterns of viral load decay under antiretroviral Erhart: influence of pharmacokinetics and intracellular delay. J. Theor. Bio. 2004;226:95–109
  21. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417:95–98
  22. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129
  23. El-Sadr W, Neaton J for the SMART Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. Abstract #106LB. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February. 2006;
  24. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction. 1996;91:1803–1820
  25. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999;5:512–517
  26. Ghosn J, Wirden M, Ktorza N, Peytavin G, Ait-Mohand H, Schneider L, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS. 2005;19:1643–1647
  27. Hairer E, Wanner G. Solving Ordinary Differential Equations II. Stiff and Differential-Algebraic Problems, vol. 14, Springer Series in Computational Mathematics. 2nd ed.. Berlin: Springer-Verlag; 1996;
  28. Hindmarsh AC. Scientific Computing, Chapter on ODEPACK, A Systematized Collection of ODE Solvers. New York: North Holland; 1983;pp. 55–64
  29. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect. Dis. 2001;1:53–59
  30. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1996;373:123–126
  31. Hser YI, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers: a conceptual framework and existing research findings. J. Subst. Abuse Treat. 1997;14:543–558
  32. Jeffrey AM, Xia X, Craig IK. When to initiate HIV therapy: a control theoretic approach. IEEE Trans. Biomed. Eng. 2003;50:1213–1220
  33. Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin. Infect. Dis. 2004;38:1447–1453
  34. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS. 2004;18:217–226
  35. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36
  36. Kelley CT. Iterative methods for optimization. Frontiers in Applied Mathematics FR18. Philadelphia: SIAM; 1999;
  37. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA. 2003;289:3095–3105
  38. Kirschner D, Lenhart S, Serbin S. Optimal control of the chemotherapy of HIV. J. Math. Bio. 1997;35:775–792
  39. Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin. Trials. 2003;1:9–20
  40. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 2003;349:837–846
  41. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863–868
  42. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 1999;340:1683–1684
  43. Lori F, Lewis MG, Xu J, Varga G, Zinn DE, Crabbs C, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 2000;290:1591–1593
  44. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001;286:2981–2987
  45. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. 2000;181:872–880
  46. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598
  47. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 2001;135:17–26
  48. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat. Med. 2005;24:1455–1481
  49. Murphy SA, Oslin DW, Rush AJ, Zhu J. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology. 2007;32:257–262
  50. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 2001;14:23–28
  51. Oxenius A, Price DA, Easterbrook PJ, O’Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2000;97:3382–3387
  52. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998;338:853–860
  53. Palella FJ, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 2003;138:620–626
  54. Perelson AS, Essunger P, Cao YZ, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–191
  55. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487–494
  56. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:393–401
  57. Rivera DE, Pew MD, Collins LM. Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction. Drug Alcohol Depend. 2007;88S:S31–S40
  58. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes B, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523–526
  59. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447–1450
  60. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;1:397–403
  61. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J. Infect. Dis. 2003;188:977–985
  62. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003;9:727–728
  63. Smith KY. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J. Infect. Dis. 2002;185:S123–S127
  64. Sobell MB, Sobell LC. Stepped care as a heuristic approach to the treatment of alcohol problems. J. Consult. Clin. Psychol. 2000;68:573–579
  65. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J. Infect. Dis. 2003;188:1659–1665
  66. Streeck H, Jessen H, Adler G, Teigen N, Waring MT, Jessen A, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J. Infect. Dis. 2006;194:734–739
  67. Vogel CR. Computational Methods for Inverse Problems, Frontiers in Applied Mathematics FR23. Philadelphia: SIAM; 2002;
  68. Walker BD, Rosenberg ES. Containing HIV after infection. Nat. Med. 2000;6:1094–1095
  69. Wein LM, Zenios SA, Nowak MA. Dynamic multidrug therapies for HIV: a control theoretic approach. J. Theor. Biol. 1997;185:14–29
  70. Wodarz D, Arnaout RA, Nowak MA, Lifson JD. Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. Phil. Trans. Roy. Soc. Lond. B. 2000;355:1021–1029
  71. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9)cells/L. Ann. Intern. Med. 2003;139:810–816
  72. Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaughnessy MV, et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J. Infect. Dis. 2003;188:1421–1425
  73. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265

PII: S0376-8716(06)00476-5

doi: 10.1016/j.drugalcdep.2006.12.024

Drug and Alcohol Dependence
Volume 88 , Pages S41-S51 , May 2007

Article Tools

* Image Usage & Resolution